By Lori Solomon HealthDay ReporterMONDAY, Aug. 11, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has ...

The sBLA for the pediatric indication is supported by data from the randomized, double-blind, placebo-controlled, phase 3 SPACE trial.

The U.S. Food and Drug Administration on Tuesday approved Ajovy, an injection made by Israeli drugmaker Teva Pharma , to help ...

The US Food and Drug Administration (FDA) has approved a label expansion to Teva’s Ajovy in certain children and adolescents, ...

FDA approves single-dose AJOVY® (fremanezumab-vfrm) injection for the preventive treatment of episodic migraine in children ...

The FDA has approved Ajovy (fremanezumab-vfrm) for preventive treatment of episodic migraine in pediatric patients aged 6 to 17 years who weigh at least 45 kg.With this approval, AJOVY becomes ...

Teva's Ajovy gains FDA approval for pediatric migraine prevention, offering hope for children aged 6-17 with this debilitating condition.

Ajovy becomes the first-and-only calcitonin gene-related peptide agonist approved for pediatric patients aged six to 17 years ...

The calcitonin gene-related peptide (CGRP) blocker was approved for adults in 2018. Fremanezumab is the first CGRP antagonist ...

Teva Pharmaceutical has received a green light from the US regulator for its biologic Ajovy (fremanezumab) to be used for ...

Migraine is prevalent among children, with an overall rate of 7.7%. This rate rises from 5% in children aged five to 10 years to around 15% in adolescents.

AJOVY® is a subcutaneous injection for the preventive treatment of migraine in adults who have at least four migraine days per month. When launched in 2020, AJOVY® was available in a prefilled ...